AnaptysBio Past Earnings Performance
Past criteria checks 0/6
AnaptysBio's earnings have been declining at an average annual rate of -13.8%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 27.5% per year.
Key information
-13.8%
Earnings growth rate
-10.3%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 27.5% |
| Return on equity | -71.5% |
| Net Margin | -1,278.9% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How AnaptysBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 11 | -137 | 40 | 0 |
| 31 Dec 22 | 10 | -129 | 37 | 0 |
| 30 Sep 22 | 4 | -135 | 29 | 0 |
| 30 Jun 22 | 24 | -108 | 26 | 0 |
| 31 Mar 22 | 53 | -76 | 23 | 0 |
| 31 Dec 21 | 63 | -58 | 21 | 0 |
| 30 Sep 21 | 122 | 8 | 21 | 0 |
| 30 Jun 21 | 101 | -9 | 21 | 0 |
| 31 Mar 21 | 71 | -30 | 20 | 0 |
| 31 Dec 20 | 75 | -20 | 19 | 0 |
| 30 Sep 20 | 18 | -74 | 18 | 0 |
| 30 Jun 20 | 18 | -81 | 17 | 0 |
| 31 Mar 20 | 23 | -84 | 16 | 0 |
| 31 Dec 19 | 8 | -97 | 16 | 0 |
| 30 Sep 19 | 5 | -94 | 16 | 0 |
| 30 Jun 19 | 10 | -79 | 16 | 0 |
| 31 Mar 19 | 5 | -69 | 16 | 0 |
| 31 Dec 18 | 5 | -62 | 16 | 0 |
| 30 Sep 18 | 8 | -52 | 14 | 0 |
| 30 Jun 18 | 3 | -45 | 13 | 0 |
| 31 Mar 18 | 10 | -34 | 11 | 0 |
| 31 Dec 17 | 10 | -30 | 9 | 0 |
| 30 Sep 17 | 10 | -27 | 8 | 0 |
| 30 Jun 17 | 13 | -19 | 6 | 0 |
| 31 Mar 17 | 12 | -15 | 5 | 0 |
| 31 Dec 16 | 17 | -4 | 4 | 0 |
| 30 Sep 16 | 18 | -4 | 4 | 0 |
| 30 Jun 16 | 19 | -4 | 4 | 0 |
| 31 Mar 16 | 18 | -6 | 4 | 0 |
| 31 Dec 15 | 18 | -5 | 4 | 0 |
| 30 Sep 15 | 17 | -2 | 3 | 0 |
| 30 Jun 15 | 19 | 0 | 3 | 0 |
| 31 Mar 15 | 18 | 1 | 3 | 0 |
| 31 Dec 14 | 16 | 0 | 2 | 0 |
| 31 Dec 13 | 5 | -6 | 2 | 0 |
Quality Earnings: ANAB * is currently unprofitable.
Growing Profit Margin: ANAB * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANAB * is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.
Accelerating Growth: Unable to compare ANAB *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANAB * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: ANAB * has a negative Return on Equity (-71.55%), as it is currently unprofitable.